GeneReach Biotechnology Corporation, headquartered in Taiwan, is dedicated to bringing innovation to global health management. By developing, manufacturing and marketing products for applied nucleic acid detection technology, we offer pathogen detection platforms, including equipment and reagents, to multiple industries. The applications of our products include aquaculture, agriculture, food, companion animal, livestock and human health industries. Our products are manufactured in compliance with the requirements of Good Manufacturing Practices (GMP) in addition to ISO 13485. Developing the high performance and user-friendly products is the major driving force of our research and development team. Based on this philosophy, GeneReach Biotechnology Corporation manufactures products which are reliable, affordable and easy to perform. Our goal is to provide the best detection products and service worldwide and down to the extreme of Point of Care market.
Contact
No.19, Keyuan 2nd Road, Central Taiwan Science Park, Taichung City 407, Taiwan
Tel: +886-4-24639869
Leo Liu, president of GeneReach Biotechnology Corp, shares the story of the diagnostics startup and explains his strategy to transition the company from a leading animal health point-of-care device manufacturer…
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular…
Writing in the June edition of DIA’s Global Forum magazine, Ellen Sem, Fengyun (Vicky) Han and Annetta C. Beauregard from Janssen Pharmaceutical Companies of Johnson & Johnson, outline the real-world data…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
Andrew Hexter, VP and GM of Gilead Asia 5 (Hong Kong, Singapore, South Korea, Taiwan and Malaysia), shares the highlights of his past three years leading the diverse region, the…
With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision…
See our Cookie Privacy Policy Here
